載入...
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
BACKGROUND: Nonpegylated liposomal doxorubicin liposomal doxorubicin, (Myocet™; Sopherion Therapeutics, Inc Canada, and Cephalon, Europe) (NPLD; Myocet(®)) in combination with trastuzumabHerceptin(®) (Hoffmann-La Roche) has shown promising activity and cardiac safety. We conducted a randomized phase...
Na minha lista:
| 發表在: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4433508/ https://ncbi.nlm.nih.gov/pubmed/24401928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt543 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|